Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Molecular Endocrinology

• Publication date

  1996-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1210/MEND.10.11.8923465PMID 8923465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A canonical structure for the ligand-binding domain of nuclear receptors

  1996cited by this paper
• Estrogen receptors: bioactivities and interactions with cell signaling pathways.

  1996cited by this paper
• Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.

  1996cited by this paper
• Identification of Amino Acids in the Hormone Binding Domain of the Human Estrogen Receptor Important in Estrogen Binding*

  1996cited by this paper
• Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones.

  1996cited by this paper
• Steroid hormone receptors: many actors in search of a plot.

  1995cited by this paper
• Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro.

  1995cited by this paper
• Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

  1995cited by this paper
• Antiestrogens: mechanisms and actions in target cells.

  1995cited by this paper
• The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.

  1995cited by this paper
• A structural role for hormone in the thyroid hormone receptor

  1995cited by this paper
• Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α

  1995cited by this paper
• Phosphorylation of Tyrosine 537 on the Human Estrogen Receptor Is Required for Binding to an Estrogen Response Element (*)

  1995cited by this paper
• Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily

  1995cited by this paper
• Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene.

  1994cited by this paper
• Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor.

  1994cited by this paper
• Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors.

  1994cited by this paper
• Characterization of ligand-dependent phosphorylation of the estrogen receptor.

  1994cited by this paper
• Molecular mechanisms of action of steroid/thyroid receptor superfamily members.

  1994cited by this paper
• Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.

  1994cited by this paper
• Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity.

  1994cited by this paper
• Properties of a purified estradiol-dependent calf uterus tyrosine kinase.

  1993cited by this paper
• Powerful dominant negative mutants of the human estrogen receptor.

  1993cited by this paper
• Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors.

  1993cited by this paper
• Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators.

  1993cited by this paper
• Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.

  1993cited by this paper
• Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region.

  1993cited by this paper
• Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I.

  1993cited by this paper
• Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination.

  1992cited by this paper
• Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor.

  1992cited by this paper
• Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding.

  1992cited by this paper
• Transcription activation by estrogen and progesterone receptors.

  1991cited by this paper
• Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors.

  1991cited by this paper
• Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells.

  1991cited by this paper
• Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor.

  1990cited by this paper
• The human estrogen receptor has two independent nonacidic transcriptional activation functions.

  1989cited by this paper
• Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding.

  1989cited by this paper
• Cooperative effects of colony-stimulating factor 1 and recombinant interleukin 2 on proliferation and induction of cytotoxicity of macrophage precursors generated from mouse bone marrow cell cultures

  1989cited by this paper
• Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme.

  1989cited by this paper
• The steroid and thyroid hormone receptor superfamily.

  1988cited by this paper
• Control of progesterone receptors in fetal uterine cells in culture: effects of estradiol, progestins, antiestrogens, and growth factors.

  1988cited by this paper
• The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function.

  1988cited by this paper
• Functional domains of the human estrogen receptor.

  1987cited by this paper
• Rapid and efficient site-specific mutagenesis without phenotypic selection.

  1987cited by this paper
• Oestradiol stimulates tyrosine phosphorylation and hormone binding activity of its own receptor in a cell‐free system.

  1987cited by this paper
• Localisation of the oestradiol‐binding and putative DNA‐binding domains of the human oestrogen receptor.

  1986cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells

  2025cites this paper
• Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancer

  2025cites this paper
• Public neoantigens in breast cancer immunotherapy (Review)

  2024cites this paper
• Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.

  2024cites this paper
• Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration

  2024cites this paper
• Deciphering the Role of BCAR3 in Cancer Progression: Gene Regulation, Signal Transduction, and Therapeutic Implications

  2024cites this paper
• Estrogen receptor alpha mutations, truncations, heterodimers, and therapies.

  2024cites this paper
• Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

  2024cites this paper
• Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs

  2023cites this paper
• FOXA1 reprogramming dictates retinoid X receptor response in ESR1 mutant breast cancer.

  2023cites this paper
• Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping

  2023cites this paper
• Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

  2022cites this paper
• Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs

  2022cites this paper
• Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer

  2022cites this paper
• Computed cancer interactome explains the effects of somatic mutations in cancers

  2022cites this paper
• Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology

  2022cites this paper
• Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR

  2022cites this paper
• The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer.

  2021cites this paper
• CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers

  2021cites this paper
• The effect of protein mutations on drug binding suggests ensuing personalised drug selection

  2021cites this paper
• Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer

  2021cites this paper
• Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer

  2021cites this paper
• The physiological role of estrogen receptor functional domains.

  2021cites this paper
• In silico elucidation of plausible inhibitory potential of Withaferin A of Withania somnifera medicinal herb against breast cancer targeting estrogen receptor.

  2020cites this paper
• Point-activated ESR1Y541S has a dramatic effect on the development of sexually dimorphic organs

  2020cites this paper
• Review ctDNA and Breast Cancer.

  2020cites this paper
• ERα, A Key Target for Cancer Therapy: A Review

  2020cites this paper
• Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment

  2020cites this paper
• Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

  2020cites this paper
• Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient

  2020cites this paper
• Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer

  2020cites this paper
• OTT_A_236532 2183..2191

  2020cites this paper
• Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects

  2020cites this paper
• Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity

  2020cites this paper
• 18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer

  2019cites this paper
• UTILITY OF AMPLIFICATION-REFRACTORY MUTATION SYSTEM FOR THE DETECTION CLINICALLY SIGNIFICANT ESTROGEN AND PROGESTERONE RECEPTORS GENE VARIATIONS IN BREAST CANCER PATIENTS

  2019cites this paper
• ERα-targeted endocrine therapy, resistance and the role of GPER.

  2019cites this paper
• De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor

  2019cites this paper
• ESR1 mutations: a new biomarker in breast cancer

  2019cites this paper
• Role of Next-Generation Sequencing Technologies in Personalized Medicine

  2019cites this paper
• Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.

  2019cites this paper
• ESR1 alterations and metastasis in estrogen receptor positive breast cancer

  2019cites this paper
• Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

  2019cites this paper
• The ER ‐ alpha mutation Y 537 S confers Tamoxifen ‐ resistance via enhanced mitochondrial metabolism , glycolysis and Rho ‐ GDI / PTEN signaling : Implicating TIGAR in somatic resistance to endocrine therapy

  2019cites this paper
• P5 eHealth: An Agenda for the Health Technologies of the Future

  2019cites this paper
• The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer

  2019cites this paper
• Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling

  2019cites this paper
• Next-Generation ER&agr; Inhibitors for Endocrine-Resistant ER+ Breast Cancer

  2019cites this paper
• Molecular characterisation of oestrogen receptor ERα and the effects of bisphenol A on its expression during sexual development in the Chinese giant salamander (Andrias davidianus).

  2019cites this paper
• Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets

  2018cites this paper
• The evolving role of receptors as predictive biomarkers for metastatic breast cancer

  2018cites this paper
• The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy

  2018cites this paper
• Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer

  2018cites this paper
• Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals

  2018cites this paper
• Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

  2018cites this paper
• Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes

  2018cites this paper
• Publisher Correction: Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

  2018cites this paper
• A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers

  2018cites this paper
• Méthodes bioinformatiques pour l'analyse de données de séquençage dans le contexte du cancer. (Bioinformatics methods for cancer sequencing data analysis)

  2017cites this paper
• Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

  2017cites this paper
• Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

  2017cites this paper
• Are We Ready to Use ESR1 Mutations in Clinical Practice

  2017cites this paper
• Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients

  2017cites this paper
• Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

  2017cites this paper
• Label-Free Biosensor Detection of Endocrine Disrupting Compounds Using Engineered Estrogen Receptors

  2017cites this paper
• Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications.

  2017cites this paper
• Personalized cancer medicine guided by liquid biopsies

  2017influential citation
• Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.

  2017cites this paper
• Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells

  2017cites this paper
• Estrogens in Male Physiology.

  2017cites this paper
• [Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer].

  2017cites this paper
• Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?

  2017cites this paper
• Advances in systemic therapy for metastatic breast cancer: future perspectives

  2017cites this paper
• ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.

  2017cites this paper
• Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

  2017cites this paper
• Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI

  2016cites this paper
• Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

  2016cites this paper
• Critical Ligand Binding Sequences of the Esr1 Gene: What Role in the Treatment of Er(+) Breast Cancers?

  2016cites this paper
• Identification of DNA sequence variants in the estrogen receptor pathway in breast cancer

  2016cites this paper
• Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

  2016cites this paper
• Metastatic breast cancer: The Odyssey of personalization

  2016cites this paper
• Endocrine treatment in breast cancer: Cure, resistance and beyond.

  2016cites this paper
• Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors

  2016cites this paper
• Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients

  2016cites this paper
• Estrogen modulates exercise endurance along with mitochondrial uncoupling protein 3 downregulation in skeletal muscle of female mice.

  2016cites this paper
• Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

  2016cites this paper
• Antiestrogens: structure-activity relationships and use in breast cancer treatment

  2016cites this paper
• ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

  2015cites this paper
• Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

  2015cites this paper
• ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

  2015cites this paper
• Estrogen receptor mutations and functional consequences for breast cancer.

  2015cites this paper
• 20to a region homologous to human chromosome A quantitative trait locus influencing estrogen levels

  2015cites this paper
• Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.

  2015cites this paper
• Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.

  2015cites this paper
• Hepatic estrogen receptor α improves hepatosteatosis through upregulation of small heterodimer partner.

  2015cites this paper
• Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer

  2015cites this paper
• Estrogen Receptor Folding Modulates cSrc Kinase SH2 Interaction via a Helical Binding Mode.

  2015cites this paper
• Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects

  2015cites this paper
• Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.

  2015cites this paper
• Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

  2015cites this paper